Meeting
2017 ASCO Annual Meeting
Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).
Authors
Elisa A. Rozeman
Netherlands Cancer Institute, Amsterdam, Netherlands
Elisa A. Rozeman , Alexander Christopher Jonathan Van Akkooi , Emilie Routier , Alexander M. Menzies , Hanna Eriksson , Myles Smith , Richard A. Scolyer , Christoph Hoeller , Johan Hansson , Caroline Robert , James M. G. Larkin , Georgina V. Long , Christian U. Blank
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT02977052
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS9600)
DOI
10.1200/JCO.2017.35.15_suppl.TPS9600
Abstract #
TPS9600
Poster Bd #
203b
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).
First Author: Elisa A. Rozeman
Poster
2019 ASCO Annual Meeting
Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.
First Author: Irene Reijers
Poster
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
First Author: Zeynep Eroglu
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.
First Author: Jianbo Wang